2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Patsenker E et al. Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. 2015 Int J Mol Sci pmid:25826533
Llorente-Berzal A et al. 2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. 2015 Psychopharmacology (Berl.) pmid:25814137
Thieme U et al. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans. 2014 Jan-Feb Drug Test Anal pmid:24424856
Shonesy BC et al. Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. 2014 Cell Rep pmid:25466252
Gasperi V et al. 2-Arachidonoylglycerol enhances platelet formation from human megakaryoblasts. 2014 Cell Cycle pmid:25427281
Zhang J et al. Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. 2014 J. Neurosci. pmid:25378159
Smaga I et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. 2014 Neurotox Res pmid:24652522
Nithipatikom K et al. A novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol. 2014 J. Lipid Res. pmid:24958911
Karabowicz P et al. [Role of endocannabinoid 2-arachidonoylglycerol in the physiology and pathophysiology of the cardiovascular system]. 2014 Postepy Hig Med Dosw (Online) pmid:24934539
Hillard CJ Stress regulates endocannabinoid-CB1 receptor signaling. 2014 Semin. Immunol. pmid:24882055
Kohnz RA and Nomura DK Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. 2014 Chem Soc Rev pmid:24676249
Pastor A et al. Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs. 2014 J. Lipid Res. pmid:24610889
Stanley CP and O'Sullivan SE Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. 2014 Pharmacol. Res. pmid:24548820
Pérez-Morales M et al. 2-Arachidonoylglycerol into the lateral hypothalamus improves reduced sleep in adult rats subjected to maternal separation. 2014 Neuroreport pmid:25356522
Signorello MG and Leoncini G Effect of 2-arachidonoylglycerol on myosin light chain phosphorylation and platelet activation: The role of phosphatidylinositol 3 kinase/AKT pathway. 2014 Biochimie pmid:25068972
Fernández-Suárez D et al. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. 2014 Neurobiol. Aging pmid:24973119
Alhouayek M et al. Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy. 2014 Drug Discov. Today pmid:23891880
Morena M et al. Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25489086
Lau BK et al. Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey. 2014 Br. J. Pharmacol. pmid:25041240
Laprairie RB et al. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. 2014 J. Biol. Chem. pmid:25037227
Cipriano M et al. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. 2014 BMC Res Notes pmid:25012825
Wiley JL et al. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. 2014 Eur. J. Pharmacol. pmid:24858366
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
Sun LJ et al. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. 2014 Int. J. Infect. Dis. pmid:24704332
Basavarajappa BS et al. Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice. 2014 Hippocampus pmid:24648181
Aaltonen N et al. Brain regional cannabinoid CB(1) receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice. 2014 Eur J Pharm Sci pmid:24012970
Brantl SA et al. Activation of platelets by the endocannabinoids 2-arachidonoylglycerol and virodhamine is mediated by their conversion to arachidonic acid and thromboxane A2, not by activation of cannabinoid receptors. 2014 Platelets pmid:24102401
Iannotti FA et al. The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:24927567
Tiburu EK and Shen L Distance measurements and conformational analysis of sn-2-arachidonoylglycerol-membrane sample by ²H-³¹P REDOR NMR. 2014 J. Membr. Biol. pmid:24402242
Costa MA et al. 2-arachidonoylglycerol effects in cytotrophoblasts: metabolic enzymes expression and apoptosis in BeWo cells. 2014 Reproduction pmid:24324206
Melis M et al. Enhanced endocannabinoid-mediated modulation of rostromedial tegmental nucleus drive onto dopamine neurons in Sardinian alcohol-preferring rats. 2014 J. Neurosci. pmid:25232109
Murataeva N et al. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. 2014 Br. J. Pharmacol. pmid:24102242
Yasuo S et al. 2-Arachidonoyl glycerol sensitizes the pars distalis and enhances forskolin-stimulated prolactin secretion in Syrian hamsters. 2014 Chronobiol. Int. pmid:24200164
Pertwee RG Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. 2014 Proc Nutr Soc pmid:24135210
Burston JJ and Woodhams SG Endocannabinoid system and pain: an introduction. 2014 Proc Nutr Soc pmid:24148358
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Yang K et al. Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus. 2014 Hippocampus pmid:25087967
Fezza F et al. Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. 2014 Mol. Cell. Neurosci. pmid:25064144
Pulgar VM et al. Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis. 2014 Hypertension pmid:24935942
Pava MJ et al. Endocannabinoid modulation of cortical up-states and NREM sleep. 2014 PLoS ONE pmid:24520411
Sanson B et al. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. 2014 Acta Crystallogr. D Biol. Crystallogr. pmid:24531463
Fowler CJ Has FLAT fallen flat? 2014 Trends Pharmacol. Sci. pmid:24398120
Rea K et al. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. 2014 Eur. J. Neurosci. pmid:24494683
Zheng Y et al. Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system. 2014 Eur. J. Pharmacol. pmid:24508383
Krishnan G and Chatterjee N Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity. 2014 Mol. Cell. Neurosci. pmid:24418364
Nicolussi S et al. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice. 2014 Pharmacol. Res. pmid:24412246
Bystrowska B et al. Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. 2014 Prog. Neuropsychopharmacol. Biol. Psychiatry pmid:24334211
Schaefer C et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. 2014 Eur Arch Psychiatry Clin Neurosci pmid:24253425
Limebeer CL et al. Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. 2014 Psychopharmacology (Berl.) pmid:24043345
Alpár A et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. 2014 Nat Commun pmid:25030704